All News

OP.density.jpg

NIH Workshop on Unmet Needs in Osteoporosis

d Jack Cush, MD

In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"

Read Article
Lupus.right_.jpg

Improved Survival in Lupus

d Jack Cush, MD

A longitudinal study of systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic has shown that mortality has decreased over time.

Read Article
RA.vascular.cholesterol.plaque.jpg

Statins in RA Patients Without CVD: Nonsignificant Results

d Jack Cush, MD

Patients with RA, but without CV disease, who were treated with atorvastatin appeared to experience cardiovascular (CV) benefits similar to what has been observed in other populations, with a risk reduction of approximately one-third, according to a large, but prematurely terminated, trial in the

Read Article
Sleep.fatigue.doctor.jpg

Sleep Myths Debunked

d Jack Cush, MD

A panel of 10 sleep experts studied 20 common sleep myths and found little or no evidence in support of these beliefs.



Sleep issues are highly prevalent among US adults, but few admit to it or do anything to manage it. 

Read Article
hidradenitis.jpg

Higher Comorbidities in Hidradenitis Suppurativa

d Jack Cush, MD

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Eat Your Veggies (4.19.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Do you use PJP prophylaxis w/ Bactrim in RA pts? 2640 RA pts found only 19 cases of pneumocystis pneumonia. Risk factors were high dose MTX (OR 4.5), >65 yrs (OR 3.7), ≥2 ISPs (3.7), prednisolone ≥5 (OR 12.4) - a combo of these has a 2.3-5.8% riskof PJP. https://t.co/5Pf2FskE30

Links:

Dr. John Cush RheumNow ( View Tweet)

Should you check hydroxychloroquine levels in your #SLE patients? I do not but probably should in patients who are not in remission as nonadherence to HCQ may be as high as 50%. This is routinely available. https://t.co/UkxjMh3lQz

Links:

Dr. John Cush RheumNow ( View Tweet)

What is your best therapy when treating calcinosis cutis? (or write in your Rx)

Dr. John Cush RheumNow ( View Tweet)

CORRONA study of 880 RA pts w/ hx of Solid cancer shows many on biologics following Dx. 42% were on biologics/tsDMARDs in the 12 mo before cancer. Post CA 31% were on same Rx, 5% switched biologics &10% started a biologic, the majority starting TNFi (54%). https://t.co/PjjQvFVnsI

Links:

Dr. John Cush RheumNow ( View Tweet)

Autoimmune dz is 4x more common in women. Studies in mice show females have increased expression of epidermal VGLL3 - known to drives proinflammatory gene expression cutaneous lupus, B cell expansion, auto-AB production, immune complex deposition. https://t.co/Le1yEBoIoR

Links:

Dr. John Cush RheumNow ( View Tweet)

RCT of 63 knee OA pts - given PBO or 40 g/d freeze-dried blueberry powder x 4 mos. Significant improvement in WOMAC total, Pain scoresand ADL scores in the blueberry group, but no change in TNFα,IL-1β, IL-6, IL-10, IL-13, MMP3, MMP-13, MCP-1 levels. https://t.co/wHzCJDOuiJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Nice quick read on periop RA management. Suspect we’re treating the surgeon more than the pt. by holding bioDMARDS, but observational data supports increased infxn risk and this algorithm seems reasonable Most of this applies to other rheum dx as well https://t.co/it6CqdKmTo https://t.co/UFe1mB2vhs

Links:

Mike Putman EBRheum ( View Tweet)
What is your best therapy when treating calcinosis cutis? (or write in your Rx)

Dr. John Cush RheumNow ( View Tweet)

Why 👏🏼are 👏🏼people👏🏼so👏🏼mean👏🏼to👏🏼each👏🏼other👏🏼in👏🏼medicine👏🏼??? We are on the same team. Sincerely, an extremely polite Intern 👩‍⚕️

jules doc__wils ( View Tweet)

Namilumab (mono ab to GM-CSF, Granulocyte-macrophage colony-stimulating factor) with good efficacy among MTX/TNF inadequate responders in a phase II RCT. NNT = 3-4 at week 12 for ACR50 at max dose. Some respiratory ADE but nothing major. https://t.co/hwHDFqCqOq https://t.co/XPsc4fjsXx

Links:

Mike Putman EBRheum ( View Tweet)
Kuddos to Philip! https://t.co/WC1EcPcz4J

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is Up! Eat Your Veggies and more about drug prices, gout, tapering, PSS mortality, insoles, Temporal arter bx & more. https://t.co/3gmVISUv9E or listen to the podcast on iTunes or SoundCloud here>> https://t.co/URNYnLd7Yi

Links:

Dr. John Cush RheumNow ( View Tweet)

Meet The Lancet Rheumatology: Advisory Board https://t.co/fA0siCsQbX

Links:

Dr. John Cush RheumNow ( View Tweet)

Phase 3 study tanezumab (anti-NGF) 2.5 mg or 5 mgin knee or hip OA find that 5 mg met 2/3 of 3 primary endpoints at 16wks; but the lower dose failed to be superior to NSAIDs in this 1 yr study. Safety outcomes where less favorable w/ tanezumab. https://t.co/l4Qffdn1nl

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×